$33.15
-0.75-2.23%
Ult. Agg.: Nov 17, 12:05 PM

Maze Therapeutics (MAZE) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 9, 2026 | $-0.79 | $-0.76 | -3.95 % |
| Q2 | Aug 11, 2026 | $-0.76 | $-0.71 | -7.04 % |
| Q1 | May 12, 2026 | $-0.45 | $-0.59 | 23.7 % |
| Q4 | Mar 25, 2026 | $-0.65 | $-0.71 | 8.45 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Nov 9, 2026 | $0 | $1.00M | -100.0 % |
| Q2 | Aug 11, 2026 | $0 | $1.82M | -100.0 % |
| Q1 | May 12, 2026 | $20.00M | $10.05M | 99.0 % |
| Q3 | Nov 6, 2025 | $0 | $2.08M | -100.0 % |
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.76 | $-0.71 | $-0.59 | $-0.71 |
| Actual | $-0.79 | $-0.76 | $-0.45 | $-0.65 |
| Surprise | -3.95% | -7.04% | +23.7% | +8.45% |
| Revenue | ||||
| Estimate | $1.0M | $1.8M | $10.1M | — |
| Actual | $0 | $0 | $20.0M | $0 |
| Surprise | -100.0% | -100.0% | +99.0% | — |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.80 | $-0.76 | $-0.79 | $-0.81 |
| Revenue | ||||
| Consensus | $2.3M | $3.1M | — | — |